BrightGene reported early Phase 1 data for BGM0504, its oral GLP-1/GIP dual agonist, showing dose-dependent weight loss after short dosing periods in both China and the U.S. In the China study (75 participants), least-squares mean weight loss at four weeks ranged from 1% to 5.6% depending on dose. In a U.S. study (80 patients), weight loss ranged from 2.7% to 8.2% after five to eight weeks. BrightGene highlighted that GI events were mostly mild and transient in China and generally mild to moderate in the U.S. The company emphasized that the data represent preliminary analyses from ongoing studies and that fuller results will be shared at a future conference. The readout adds to mounting competitive pressure in oral obesity therapeutics, where Novo Nordisk’s early oral GLP-1 launch and Eli Lilly’s oral small-molecule progress have raised the bar for efficacy, tolerability, and dosing convenience. BrightGene also noted it is advancing a subcutaneous version of BGM0504 and running head-to-head obesity work against Eli Lilly’s Zepbound. For investors, the central issue will be whether oral efficacy durability and tolerability trends in later-phase studies match or exceed injectable benchmarks as the field narrows to assets that can deliver meaningful outcomes with manageable side effects.